The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Hengrui Pharmaceutical; Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; Puma Biotechnology; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Adrianus De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Tae Min Kim
Consulting or Advisory Role - AstraZeneca/MedImmune; Hanmi; Janssen Oncology; Novartis; Takeda; Yuhan
Speakers' Bureau - Roche/Genentech; Takeda
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Roche/Genentech; Sanofi
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace; Takeda
Research Funding - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Turning Point Therapeutics
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Lilly; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda; Tesaro
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Julia K Rotow
Honoraria - AstraZeneca; Chia Tai Tianqing; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Pfizer; Regeneron; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Gritstone Bio; Lilly; Regeneron; Takeda
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Genentech/Roche; Janssen Oncology; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Merck
Other Relationship - AstraZeneca
 
Ticiana Leal
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Daiichi-Sankyo; Eisai; EMD Serono; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Mirati Therapeutics; Novocure; Takeda
 
Faris Albayya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Sarah Fitzpatrick
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Melinda Louie-Gao
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Jagan Parepally
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Alena Zalutskaya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines; Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma